Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Cancer drugs are closing in on some of the deadliest mutations

3D rendering of the KRAS protein

Chemists have struggled to design drugs that interact with the KRAS protein’s relatively smooth surface. Credit: Alamy

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature 610, 620-622 (2022)



  1. Skoulidis, F. et al. N. Engl. J. Med. 384, 2371–2381 (2021).

    Article  PubMed  Google Scholar 

  2. Fakih, M. G. et al. Lancet Oncol. 23, 115–124 (2022).

    Article  PubMed  Google Scholar 

  3. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013).

    Article  PubMed  Google Scholar 

  4. Wang, X. et al. J. Med. Chem. 65, 3123–3133 (2022).

    Article  PubMed  Google Scholar 

  5. Canon, J. et al. Nature 575, 217–223 (2019).

    Article  PubMed  Google Scholar 

  6. Zhang, Z. et al. Cancer Cell 40, 1060–1069 (2022).

    Article  PubMed  Google Scholar 

Download references


Latest on:

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links